Skip to search formSkip to main contentSkip to account menu

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
After TGN1412: Recent developments in cytokine release assays
The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically… 
Highly Cited
2011
Highly Cited
2011
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Human volunteers receiving TGN1412, a humanized CD28-specific monoclonal antibody, experienced a life-threatening cytokine… 
Highly Cited
2010
Highly Cited
2010
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cells
BACKGROUND AND PURPOSE In 2006, a life‐threatening ‘cytokine storm’, not predicted by pre‐clinical safety testing, rapidly… 
Review
2010
Review
2010
TGN1412: From Discovery to Disaster
  • H. Attarwala
  • Journal of Young Pharmacists
  • 2010
  • Corpus ID: 16305905
After a drug is confirmed as safe and efficacious in preclinical studies, it is tested in healthy human volunteers for first in… 
Highly Cited
2010
Highly Cited
2010
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
Highly Cited
2008
Highly Cited
2008
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Highly Cited
2007
Highly Cited
2007
“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics
The CD28-specific mAb TGN1412 rapidly caused a life-threatening “cytokine storm” in all six healthy volunteers in the Phase I… 
Highly Cited
2006
Highly Cited
2006
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of… 
Review
2006
Review
2006
Establishing risk of human experimentation with drugs: lessons from TGN1412
Highly Cited
2006
Highly Cited
2006
Learning from the TGN1412 trial
  • M. Goodyear
  • BMJ : British Medical Journal
  • 2006
  • Corpus ID: 32298471
This experience should foster an open culture in medical research 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)